Migraine Market

Migraine Market Overview

Migraine Market Size was valued at USD 5.68 Billion in 2023. The Global Migraine industry is projected to grow from USD 6.00 Billion in 2024 to USD 8.42 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.83% during the forecast period (2024 - 2032).

Growing public awareness of novel drug classes and the Global increase in migraine problems are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Two variables impacting the target market's expansion are an increase in migraine issues worldwide and growing public knowledge of novel medication classes. The development of this business is also projected to be aided by the arrival of calcitonin gene-related peptide (CGRP). A migraine is a frequent, intense headache accompanied by nausea, phonophobia, and photophobia. The disorder develops in part as a result of genes. 

Emotions that are out of balance, such as despair, stress, worry, shock, and enthusiasm, might result in migraine headaches. The duration and severity of each migraine attack vary, usually affecting a single side of the head. An upsurge in the frequency of migraines with significant unmet requirements, expanding R&D spending producing a large pipeline of medications, and growing knowledge of migraine and treatment alternatives are all factors.

Over the projected period, the market will benefit from the numerous strategic actions taken by the major market players, including product releases, product approvals, and mergers and acquisitions. An increase in migraine prevalence drives the market for migraine medications. Additionally, a rise in the female population and a rise in patient awareness of migraine prevention and treatment are major drivers of market expansion. 

However, one issue impeding market expansion is the negative effects connected with migraine medication. On the other hand, it is anticipated that the important companies will have new prospects due to the growth opportunities in rising nations. Most currently available medications are licensed for the acute version of the illness, with generic triptans serving as the most common.

With the advent of CGRP-based medicines and the acceptance of novel medication classes like ditans, gepants, and the reformulation of triptans for both chronic and episodic migraine, the industry is observing a shift in terms of significant R&D. Therefore, during the forecast period, the market is anticipated to increase. However, throughout the projection period, a lack of accurate diagnosis, undiagnosed cases, and drug side effects could hinder the growth of the migraine therapeutics market. 

The market is also anticipated to expand due to the growing female population and elevated patient knowledge of migraine treatment and prevention. The negative effects associated with migraine treatments, however, are a factor limiting the market's growth. Contrarily, the major players are projected to profit from the growth opportunities in emerging nations.

Migraine Market Trends

• Growing public awareness of novel drug classes and the Global increase in migraine problems boost the market growth

Growing public awareness of novel drug classes and the Global increase in migraine problems are two factors influencing the growth of the target market. In addition, the introduction of calcitonin gene-related peptide (CGRP) is anticipated to fuel this industry's expansion. A migraine is a specific kind of severe, recurrent headache accompanied by phonophobia, photophobia, and nausea. Genes play a role in the development of the condition. However, unbalanced emotions like depression, stress, anxiety, shock, and excitement can cause migraine attacks. Each migraine episode differs in length and intensity, typically affecting one side of the head. To treat headaches brought on by migraines, migraine medications are used. 

The market for migraine medications is being driven by increased migraine prevalence. Additionally, the market is expected to grow due to the rise in the female population and increased patient awareness of migraine prevention and treatment. But a factor impeding the market's expansion is the side effects connected to migraine medications. Contrarily, the key players are anticipated to benefit from the growth opportunities in emerging nations.

Women tend to experience migraines more frequently than men do. The ratio of female to male migraine sufferers was found to be 3:1 in the world's population in 2018, according to the Migraine Association of Ireland. This is explained by how estrogen levels fluctuate in females, particularly during menstruation. In addition, hormonal drugs like oral contraceptives and hormone replacement therapy may worsen women’s migraines. Therefore, the growing female population is anticipated to fuel the market for migraine medications.

Migraine is a neurological medical condition that causes severe, excruciating headaches. The symptoms could include numbness, nausea, vomiting, and difficulty speaking. Additionally, genetically linked migraines can affect people of all ages. Food allergies, alcohol, hormonal changes, stress, and other outside factors can all contribute to a throbbing headache. Most migraine sufferers can treat themselves.

Nevertheless, analgesics, non-steroidal anti-inflammatory drugs, antipsychotics, and additional medications are required in extreme cases. Younger people are now more likely to experience migraines due to the rising popularity of an inactive lifestyle. Future market growth is anticipated to be positively impacted by it has enhanced the Migraine market CAGR globally in recent years.

Migraine Market Segment Insights

Migraine Type Insights

Based on type, the Market segments of Migraine includes Episodic and Chronic. The Episodic segment held the majority share in 2022 concerning the Migraine Market revenue. Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed and taken at the first sign of a migraine in patients who experience a few (one or two) migraines per month. Triptans, which can be combined with NSAIDs, are being prescribed as first-line treatments for patients who experience migraines more frequently. 

Doctors look to prescribe oral preventive medication, such as antidepressants, anti-epileptics, and beta-blockers, in cases where the patient experiences four or more attacks per month. Various nations in the 7MM use different kinds of specific preventive care.

Figure 1: Migraine Market by Types, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Migraine Treatment Type Insights

Based on treatment type, the Migraine Market segmentation includes Preventive and Abortive. The Abortive segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Beta-blockers like atenolol and propranolol and anti-epileptic drugs like topiramate and divalproex sodium are among the off-label and generic medications that may be prescribed as Abortive or prophylactic treatment. 

The only medications authorized for migraine prevention are Botox (neurotoxin) by Allergan, Aimovig by Amgen/Novartis, and Ajovy (CGRP mAb) by Teva. However, Botox does not relieve episodic migraines and calls for more than 30 injections across the neck, shoulders, and forehead implants for Migraines positively impact the market growth.

Migraine Drug Class Insights

The Migraine Market data has been bifurcated by surgery into Triptans, Ergots, and Others. The Triptans segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Specific painkillers for migraines include triptan medications. They are thought to function by undoing the brain changes that may result in migraine headaches. They lead to a narrowing or contracting of the blood vessels surrounding the brain. This stops the blood vessel widening, which is thought to be a migraine symptom.

News:

The US Food and Drug Administration has given the drug manufacturer final approval to distribute topiramate extended-release pills in concentrations of 25 mg, 50 mg, 100 mg, and 200 mg, according to Ajanta Pharma Ltd. This approval strengthens Ajanta Pharma's commitment to supplying the market with high-quality generic drugs and adds significantly to its growing portfolio. The generic version of Trokendi XR, manufactured by Supernus Pharmaceuticals Inc., is topiramate in extended-release form. Both migraine prevention and the treatment of epileptic convulsions are accomplished with it. 

The business obtained a grand total of 50 final Abbreviated New Drug Application (ANDA) clearances, with 41 of them presently in commercial production. Ajanta also has 22 ANDAs pending US FDA approval and two tentative approvals.

Migraine Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The Asia Pacific Migraine market is expected to exhibit a significant CAGR growth during the study period. The size of the Asia Pacific acute migraine treatment market is expected to increase due to rising healthcare costs and improving infrastructure in developing nations like China and India. Another important factor likely accelerating the regional market is the simple accessibility of affordable treatment options for migraines supported by rising regulatory body initiatives. By the India Brand Equity Foundation.

According to the Indian Business Environment Forum (IBEF), the country's healthcare system will be worth US$ 349.1 billion by FY22. Due to the rising demand for high-quality, reasonably priced healthcare, this nation's penetration of health insurance will likely increase.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: MIGRAINE MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s Migraine market accounts for the second-largest market share. Growing public awareness of novel drug classes and the global increase in migraine problems are two factors influencing the growth of the target market. In addition, the introduction of calcitonin gene-related peptide (CGRP) is anticipated to fuel this industry's expansion. Further, the Germany market of Migraine held the largest market share, and the UK market of Migraine was the fastest-growing market in the European region.

The North America Migraine Market is expected to grow at the fastest CAGR from 2024 to 2032. Growing investments from influential parties based in the U.S. S. According to estimates, extensive research and development efforts made in the United States, Canada, and other countries to find new treatment options will benefit the local market. The American Family Physician estimates roughly 441.5 million adults in the U.S., with 6 to 9 percent of men and 18 to 26 percent of women. 

The U.S. possesses experienced a migraine in 2009. Over 17 billion US dollars are spent directly on migraines each year. This pattern will persist over the forecast period, driving the North American market forward. Moreover, the US market of Migraine held the largest market share, and the CANADA market of Migraine was the fastest-growing market in the Asia-Pacific region.

Migraine Key Market Players & Competitive Insights

Major market players are spending much on R&D to increase their product lines, which will help the market of Migraine grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Migraine industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Global Migraine industry to benefit clients and expand the market sector. The Migraine industry has provided medicine with some of the most significant benefits in recent years. The Migraine market major players include Sanofi SA, Abbott Laboratories, Teva Pharmaceutical Industries Limited, Allergan Plc, Pfizer Inc, AstraZeneca, Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Impax Laboratories., and others are working on expanding the market demand by investing in research and development activities.

Sanofi SA is a cutting-edge global healthcare organization whose sole motivation is to pursue scientific breakthroughs to enhance people's quality of life. Our teams work to change the way medicine is done so that patients can have the unthinkable made possible. Millions of people benefit from our life-saving vaccines and potentially life-changing treatments, and some of the world's poorest nations have affordable access to our medications.

Also, Abbott Laboratories We are committed to realizing the promise of human potential in all contexts, facets, and phases of life. We consider that promise to be largely dependent on health. We can accomplish anything when we are in good health. And because of this, we will always strive to support people in achieving their optimal level of health at every stage of their lives. This is how we live out that conviction every day.

Key Companies in the market of Migraine include

• Sanofi SA
• Abbott Laboratories
• Teva Pharmaceutical Industries Limited
• Allergan Plc
• Pfizer Inc
• AstraZeneca
• Johnson & Johnson
• Endo International Plc
• GlaxoSmithKline Plc
• Impax Laboratories.

Migraine Industry Developments

November 2020: reported that rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, received a favorable opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The oral dissolving tablet form of Rimegepant, which comes in a 75 mg dose, is advised for use in episodic migraine prevention in adults who experience at least four migraine attacks per month and the acute treatment of migraine with or without aura in adults.

November 2020: Elyxyb (celecoxib oral solution), a new quick-acting liquid medication, was introduced by BioDelivery Sciences in January 2022. It is one of the first adults’ ready-to-use oral solutions for the acute treatment of migraine, with or without aura, that the Food and Drug Administration has approved.

Migraine Market Segmentation

Migraine Type Outlook

• Episodic
• Chronic

Migraine Treatment Type Outlook

• Preventive
• Abortive

Migraine Drug class Outlook

• Triptans
• Ergots
• Others

Migraine Regional Outlook

North America

• US
• Canada

Europe

• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Australia
• Rest of Asia-Pacific

Rest of the World

• Middle East
• Africa
• Latin America